Related Experiment Video
Updated: Mar 14, 2026
06:16
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
2.0K
The evolution of recombinant thrombolytics: Current status and future directions
Adivitiya1, Yogender Pal Khasa1
1a Department of Microbiology , University of Delhi South Campus , New Delhi , India.
Bioengineered
|October 5, 2016
Summary
Cardiovascular disorders are increasing globally. Researchers are developing advanced thrombolytic agents, moving from early enzyme therapies to novel direct fibrinolytic molecules for safer and more effective clot removal.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Cardiovascular disorders are a growing global health concern, driven by factors like obesity, hypertension, and diabetes.
- Early treatments for blood clots included antiplatelet and anticoagulant therapies, followed by enzyme-based thrombolytics (streptokinase, urokinase) which caused systemic hemorrhage.
- Second and third-generation plasminogen activators (e.g., anistreplase, t-PA variants) improved safety and efficacy, with enhanced fibrin specificity.
Purpose of the Study:
- To review the evolution of thrombolytic therapies for cardiovascular disorders.
- To highlight advancements in fibrinolytic agents, focusing on improved safety, efficacy, and specificity.
- To explore future directions in direct thrombolytic drug development and targeted delivery.
Main Methods:
- Literature review of historical and current thrombolytic agents.
- Analysis of the development of plasminogen activators and their variants.
- Discussion of novel direct thrombolytics from natural sources and liposome-based delivery systems.
Main Results:
- Enzyme-based thrombolytics like streptokinase and urokinase, while effective, posed a risk of systemic hemorrhage.
- Third-generation tissue plasminogen activator (t-PA) variants demonstrated improved stability, safety, efficacy, and fibrin specificity.
- Emerging direct fibrinolytic agents, including plasmin variants and novel molecules from microbial, plant, and animal sources, show promise for targeted delivery and administration.
Conclusions:
- The development of thrombolytic agents has progressed significantly, addressing safety and efficacy concerns.
- Future thrombolytic therapies are moving towards direct fibrinolytic action with enhanced specificity and targeted delivery, potentially using liposome technology.
- Novel thrombolytic molecules from diverse natural origins offer a promising avenue for safer and more convenient clot dissolution treatments.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:29Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K